Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Phase 1 Completed 167 enrolled Novartis Pharmaceuticals

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma, and the preliminary efficacy of gevokizumab in combination with the SOC anti-cancer therapy in subjects with mCRC and mGEC.

Timeline

Start: 2019-05-22
Primary completion: 2023-03-01
Completion: 2025-02-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	gevokizumab	Monoclonal antibody	—	Intravenous
Background	Bevacizumab	Monoclonal antibody	—	Intravenous
Background	Cabozantinib	Small molecule	60 mg	Oral
Background	Irinotecan	Small molecule	—	Intravenous
Background	Leucovorin	Small molecule	—	Intravenous
Background	Levoleucovorin	Unknown	—	Intravenous
Background	Oxaliplatin	Small molecule	—	Intravenous
Background	Paclitaxel	Small molecule	—	Intravenous
Background	Ramucirumab	Monoclonal antibody	—	Intravenous
Background	fluorouracil	Small molecule	—	Intravenous

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Summary

Timeline

Drugs

Indications